-
1 month ago | 
publications.ersnet.org | Gerard J. Criner |David Lipson |Lee Tombs |MeiLan K Han |Meilan Han
Research Letter Open access Effects of seasonality and treatment on COPD clinical outcomes: IMPACT post hoc analysis ArticleFigures & TablesInfo & Metrics To the Editor:COPD exacerbation rates vary during the year, with higher rates and a greater proportion of patients experiencing exacerbations in the winter months [1, 2].
-
Dec 18, 2024 | 
bmcgenomics.biomedcentral.com | Min Hyung Ryu |Jeong Yun |Kangjin Kim |Michele Gentili |Auyon J Ghosh |Frank C. Sciurba | +10 more
465 subjects met the case criteria for COPD, 213 subjects met the case criteria for IPF, and 348 subjects met the control criteria. Demographic and clinical characteristics of the 1,026 subjects included in our analysis are shown in Table 1. Notably, IPF subjects were predominantly male (70%). The cohort included 90% of self-identified white subjects. COPD subjects were predominantly smokers (95.2% have ever smoked) and IPF and control subjects were 65.3% and 67.8% ever smokers, respectively.
-
Oct 9, 2024 | 
healio.com | Richard Gawel |Kristen Dowd |Gerard J. Criner |Arianne K. Baldomero
Gerard J. Criner, MD, FACP, FACCP These findings are significant and shed light on an understudied problem — women who suffer from COPD and lack of access to appropriate health care because of poverty, higher education, poor internet access and higher rates of comorbid conditions. To mitigate these disparities, doctors can provide better education to these patients about their disease, use telemedicine for patient care and lobby for greater access despite their rural location.
-
Sep 9, 2024 | 
healio.com | Isabella Hornick |Kristen Dowd |Gerard J. Criner
Read more You've successfully added COPD to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways: Compared with baseline, FEV1 increased 5 years after Zephyr Valve treatment. The proportion of patients reporting a respiratory serious adverse event went down after year one.
-
Jun 1, 2024 | 
rc.rcjournal.com | Gerard J. Criner |Daedalus Enterprises
-
May 21, 2024 | 
healio.com | Isabella Hornick |Kristen Dowd |Gerard J. Criner
You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways: At the moment, targeted lung denervation as a treatment for COPD has only been performed in research. Quality of life and COPD symptoms improved in the 2 years following this treatment.
-
Apr 18, 2024 | 00113-6/abstract?rss=yes&sz=64)
resmedjournal.com | T. David Koster |Pallav L. Shah |Arschang Valipour |Klinik Floridsdorf |Gerard J. Criner |Felix J.F. Herth | +9 more
Endobronchial Valve Therapy in Patients with Homogeneous Emphysema. Results from the IMPACT Study. Am J Respir Crit Care Med. 2016; 194: 1073-1082Endobronchial Valves for Emphysema without Interlobar Collateral Ventilation. N Engl J Med. 2015; 373: 2325-2335A Multicenter Randomized Controlled Trial of Zephyr Endobronchial Valve Treatment in Heterogeneous Emphysema (TRANSFORM). Am J Respir Crit Care Med.
-
Jan 1, 2024 | 
openres.ersjournals.com | Judith Brock |Frank C. Sciurba |Gerard J. Criner |Felix J. F. Herth
IntroductionCOPD remains a major healthcare issue with a global impact, currently being the fourth leading cause of death worldwide [1]. The high impact of morbidity and mortality associated with COPD includes a significant economic burden, with COPD accounting for >50% of the direct costs of respiratory disease, and an impact on productivity at work and home.
-
Dec 15, 2023 | 00387-6/fulltext?rss=yes&sz=64)
resmedjournal.com | Marc Miravitlles |Gerard J. Criner |Marcus A. Mall |Humboldt-Universität zu Berlin
Highlights •Acquired CFTR dysfunction, often induced by cigarette smoke exposure, may contribute to systemic comorbidities commonly seen in patients with COPD and the chronic bronchitis phenotype of COPD. •New CFTR modulating therapies may alter the pathophysiology of COPD and chronic bronchitis, in the lungs and systemically, to improve comorbidities.
-
Sep 12, 2023 | 
breathinglabs.com | Gerard J. Criner
Gerard J. Criner, MD, FACP, FACCPIn general, optimal medical treatment of patients with COPD includes pharmacological treatment with inhaled respiratory drugs that dilate the airways (bronchodilators) and decrease airways inflammation (inhaled steroids) and nonpharmacological treatments (oxygen and pulmonary rehabilitation).
